We are a Swiss pharmaceutical wholesaler, specialized in sourcing and delivering pharma products, medical devices and drugs from and to all over the world.
We are delighted to invite you to come and meet us at the 27th EAHP (The European Association of Hospital
A new research published in Neuropathology and Applied Neurobiology, has established that Toxic proteins within the brain that cause Parkinson’s
300 million people worldwide are living with a rare disease and today it is RARE DISEASE DAY. We, at Elixi,
We are overly excited to welcome our new Export Manager, Federica Davitti, into the Elixi team! Federica has more than 20
Thank you Arab Health!!!! we had a blast!!! #teamspirit #arabhealth https://www.linkedin.com/feed/update/urn:li:activity:7027248432746508288
We are extremely proud and excited to announce the latest addition to our ” dream team” at Elixi! Fabio Macchi has recently
EMA has recommended a conditional marketing authorisation in the European Union (EU) for Carvykti (ciltacabtagene autoleucel) for the treatment of adult patients
The U.S. Food and Drug Administration approved Jardiance (empagliflozin) to reduce the risk of cardiovascular death and hospitalization for heart
EMA has recommended granting a marketing authorisation in the European Union (EU) for Kimmtrak (tebentafusp), a monotherapy for the treatment of adult
Vicolo Oldelli 1
6830 Chiasso / Switzerland
Email info@elixi-int.com
Phone/Fax +41 91 6822040
Copyright 2022 ELIXI International SA. | All Rights Reserved | Privacy Policy | Cookie Policy
